1. Home
  2. NMFC vs GYRE Comparison

NMFC vs GYRE Comparison

Compare NMFC & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Mountain Finance Corporation

NMFC

New Mountain Finance Corporation

N/A

Current Price

$6.38

Market Cap

636.6M

Sector

Finance

ML Signal

N/A

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

N/A

Current Price

$4.22

Market Cap

625.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NMFC
GYRE
Founded
2010
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
636.6M
625.6M
IPO Year
2010
2004

Fundamental Metrics

Financial Performance
Metric
NMFC
GYRE
Price
$6.38
$4.22
Analyst Decision
Hold
Strong Buy
Analyst Count
7
3
Target Price
$8.13
★ $18.67
AVG Volume (30 Days)
★ 705.5K
210.5K
Earning Date
11-02-2026
11-05-2026
Dividend Yield
★ 15.60%
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $275,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$27.49
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$6.31
$3.97
52 Week High
$9.84
$9.14

Technical Indicators

Market Signals
Indicator
NMFC
GYRE
Relative Strength Index (RSI) 31.37 36.73
Support Level N/A $3.97
Resistance Level $7.26 $7.28
Average True Range (ATR) 0.17 0.38
MACD -0.05 0.04
Stochastic Oscillator 10.00 27.71

Price Performance

Historical Comparison
NMFC
GYRE

About NMFC New Mountain Finance Corporation

New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: